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 Abstract 
Autoantibodies have been detected in systemic sclerosis patients and typical clinical features regarding 
organ involvement by each autoantibody have been reported. To reveal differences in exercise intolerance 
in patients with either anti-topoisomerase-I or anti-centromere antibodies, 53 systemic sclerosis patients 
were investigated retrospectively. A 6-minute walking distance showed no significant differences (P = 
0.090) between autoantibodies, while exercise-induced hypoxia during the 6-minute walking test was 
significant in subjects with the anti-topoisomerase-I antibody (P = 0.033). The percent predicted of vital 
capacity, the diffusion capacity of the lung for carbon monoxide, and the modified Rodnan skin score 
were affected more in subjects with the anti-topoisomerase-I antibody than the anti-centromere antibody. 
The main parameter affecting the 6-minute walking distance was the percent predicted of vital capacity 
for each autoantibody, and there was a significant positive relationship for all subjects (R2 = 0.30, P < 
0.0001). Exercise-induced hypoxia was also shown in the more affected subjects in the percent predicted 
of vital capacity and the diffusion capacity of the lung for carbon monoxide. Lung parameters were 
suggested to be more important factors determining exercise intolerance and induced hypoxia than 
detected autoantibodies. 
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 Introduction 
Systemic sclerosis (SSc) is classified into two subsets, diffuse cutaneous SSc and limited cutaneous SSc, 
according to the extent of skin lesions. Some autoantibodies in sera found in SSc patients include 
anti-topoisomerase-I and anti-centromere antibodies [1-3]. The anti-topoisomerase-I antibody likely 
causes diffuse cutaneous SSc and a significant increased risk of lung and heart involvement. In contrast, 
the anti-centromere antibody causes limited cutaneous SSc and less organ involvement. 
 Exercise intolerance was also examined in SSc patients regarding organ dysfunction [4], and interstitial 
lung disease was suggested to be important in predicting mortality [5]. However, there are few studies 
regarding the role of autoantibodies on exercise capacity. The anti-topoisomerase-I antibody (anti-Sel-70 
autoantibody) was reported to be a factor determining oxygen desaturation during the 6-minute walking 
test (6MWT), where compared autoantibodies in the analysis were unclear [6].  
 The aim of this study is to reveal the role of autoantibodies on exercise capacity. Since possible organ 
involvement by each autoantibody is becoming clear, it must be established whether exercise intolerance 




Fifty three consecutive SSc patients with either anti-topoisomerase-I or anti-centromere antibodies who 
could perform the 6MWT were assigned to this study retrospectively (Table 1). Patients were referred as 
part of their routine evaluation for treatment. Evaluations were performed during their first visit to our 
facility from 2007 to 2011. The study was approved by the Ethics Committee of our facility. Oxygen 
saturation (SpO2) was monitored during the 6MWT. The SpO2 value was sufficiently high in all subjects 
(> 95%) at rest, while a decrease from baseline ≥ 4% after the 6MWT was defined as exercise-induced 
hypoxia. Percent predicted of vital capacity (VC) and the diffusion capacity of the lung for carbon 
monoxide (DLCO) from spirometry were collected as pulmonary parameters. Skin involvement was 
evaluated by the modified Rodnan skin score.  
 
Statistics 
Walking distance was calculated as a percent of predicted values by the Enright formula [7] taking gender, 
age, height, and weight into consideration. Differences in evaluation values between the two 
autoantibodies were compared using the t test. The chi-square test was used for comparison of sex 
distribution, subset of disease, and exercise-induced hypoxia. Simple linear regression between the 
6MWT distance and parameter values was performed for each autoantibody. Statistical analyses were 




The anti-topoisomerase-I antibody was detected in 37 of 53 subjects and 30 of them were diagnosed with 
diffuse cutaneous SSc, whereas all 16 subjects with the anti-centromere antibody had limited cutaneous 
SSc (Table 1). There was no difference in sex distribution between the autoantibodies, though age was 
significantly higher and duration of disease after onset of Raynaud’s phenomenon tended to be longer in 
subjects with the anti-centromere antibody. There was no significance in the 6MWT distance between 
autoantibodies (P = 0.090), while hypoxia induced by the 6MWT was significant in subjects with the 
anti-topoisomerase-I antibody (P = 0.033). Moreover, percent predicted of VC, DLCO, and the modified 
Rodnan skin score were more affected in subjects with the anti-topoisomerase-I antibody than the 
anti-centromere antibody. 
 The only parameter affecting the 6MWT distance was percent predicted of VC for each autoantibody 
(Table 2). The regression line between the 6MWT distance and percent predicted of VC for all subjects 
represented a positive relationship (R2 = 0.30, P < 0.0001) (Figure 1). Induced hypoxia was shown in the 
more affected subjects in percent predicted of VC and DLCO, but not in age, duration of disease, or the 
6MWT distance (Table3). 
 
Discussion 
In this study, as supported by previous studies [1, 3], lung and skin involvement was found in SSc with 
the anti-topoisomerase-I antibody more than that with the anti-centromere antibody. Moreover, the 
tendency of a longer duration from the onset of disease without severe organ dysfunction in subjects with 
the anti-centromere antibody was suggested by the rapid progress in lung involvement by the 
anti-topoisomerase-I antibody [8]. 
 The main aim of this study was to define the limiting factors of exercise capacity. The distance of the 
6MWT tended to be shorter in SSc with the anti-topoisomerase-I antibody than that with the 
anti-centromere antibody, but there was no significant difference despite distinguishable lung and skin 
involvement. However, simple linear regression analysis showed a clear relationship between the 6MWT 
distance and percent predicted of VC. These results suggested exercise intolerance was mainly caused by 
lung dysfunction, which was also shown in subjects with the anti-centromere antibody. 
 Exercise-induced hypoxia was more common in SSc with the anti-topoisomerase-I antibody than that 
with the anti-centromere antibody [6]. Since there were only three subjects with the anti-centromere 
antibody showing induced hypoxia, it was difficult to detect the affecting factors on induced hypoxia 
divided by each autoantibody. Lung involvement was significantly severe in subjects with induced 
hypoxia; however skin involvement and/or exercise capacity did not affect oxygen saturation. Therefore, 
there remained the possibility that induced hypoxia was also caused by lung involvement, and not by 
autoantibodies per se. 
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 Other autoantibodies include anti-RNA polymerase, anti-U1-RNP, and anti-U3-RNP antibodies. As the 
anti-U1-RNP antibody is known to cause isolated pulmonary arterial hypertension [9], there is the 
possibility that a different relationship could exist between exercise capacity and examined parameters. 
This is because exercise capacity could also be reduced by pulmonary arterial hypertension [6, 10]. The 
distribution of autoantibodies in SSc has regional variety [3], and there were only two patients with the 
anti-U1-RNP antibody in this study. We excluded such a small number of cases and examined only two 
major autoantibodies. In the 53 subjects in this study, there was no relationship between the 6MWT 
distance and right ventricular systolic pressure (R2 = 0.0013, P = 0.79), which may be the result of 
comparatively low pulmonary arterial pressures in these subjects. 
 Detection of autoantibodies would be beneficial to SSc patients for predictive prognosis concerning 
organ involvement. Even though the anti-centromere antibody has less of an effect on organs than that of 
the anti-topoisomerase-I antibody, organ involvement could not be avoided in disease of a long duration. 
Lung parameters were suggested to be important determinants of exercise intolerance and induced 
hypoxia in spite of whichever autoantibody was positive. In conclusion, careful examination of organ 
involvement is necessary regarding exercise capacity even after detection of autoantibodies. 
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 Table 1 Characteristics of subjects 
Parameters Anti-topoisomerase-I antibody Anti-centromere antibody P 
Sex (f/m)    32/5 15/1 0.65 
Age, y 54.3 ± 12.3 63.0 ± 8.9 0.0062 
Duration of disease, y 5.0 ± 5.1 10.9 ± 11.1 0.057 
Subset (diffuse/limited) 30/7 0/16 NA 
Vital capacity (% pred) 85.5 ± 22.9 110.6 ± 20.3 0.0004 
DLCO (% pred) 53.9 ± 16.8 68.2 ± 19.9 0.019 
MRSS 14.6 ± 9.9 3.6 ± 4.3 < 0.0001 
6MWT distance (% pred) 85.7 ± 15.7 95.1 ± 18.8 0.090 
Induced hypoxia/negative 20/17 3/13 0.033 
Values are mean ± SD. MRSS: the modified Rodnan skin score; 6MWT: six-minute walking test; NA: not 
available. 
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 Table 2 Simple linear regression analysis between the 6MWT distance and parameters 
Parameters Anti-topoisomerase-I antibody Anti-centromere antibody 
R2 P R2 P 
Vital capacity (% pred) 0.22 0.0034 0.33 0.020 
DLCO (% pred) 0.016 0.46 0.13 0.18 
MRSS 0.086 0.079 0.044 0.44 
MRSS: the modified Rodnan skin score. 
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 Table 3 Effects of parameters on exercise-induced hypoxia 
Parameters Induced hypoxia Negative response P 
Age, y 57.3 ± 10.7 56.7 ± 13.0 0.85 
Duration of disease, y 6.0 ± 4.5 7.3 ± 9.7 0.51 
Subset (diffuse/limited) 17/6 13/17 0.049 
Vital capacity (% pred) 78.3 ± 21.2 104.3 ± 21.5 < 0.0001 
DLCO (% pred) 45.4 ± 13.2 68.1 ± 16.4 < 0.0001 
MRSS 12.7 ± 9.8 10.3 ± 10.1 0.38 
6MWT distance (% pred) 86.4 ± 19.4 90.1 ± 15.2 0.45 
Values are mean ± SD. MRSS: the modified Rodnan skin score; 6MWT: six-minute walking test. 
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Relationship of percent predicted of vital capacity to the 6MWT distance. Closed circles represent the 
anti-topoisomerase-I antibody and open circles represent the anti-centromere antibody. The regression 
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